Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- PL Intelligence
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- PL Intelligence
- Overview
- Industry news
- Deals review
- Press releases
- Articles
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing
is a division of
is a division of
- Companies
- Company details
Gemin X Biotechnologies
· Gemin X Biotechnologies seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis.The company in detail
Summary
Gemin X Biotechnologies was established in late 1998, in Montréal, Québec as a spin-out of McGill University. The company completed a second round funding in May 2001. Gemin X Biotechnologies seeks to discover and develop advanced oncology therapeutics based on the modulation of apoptosis. The company's mission is to develop integrated capabilities in target discovery and validation, high-throughput screening, medicinal chemistry and preclinical development form the core of the company's discovery engine.
R&D
To view this information, you must subscribe to PL Intelligence.
Partnerships
To view this information, you must subscribe to PL Intelligence.
Latest News
To view this information, you must subscribe to PL Intelligence.
Senior management
To view this information, you must subscribe to PL Intelligence.
Board of directors
To view this information, you must subscribe to PL Intelligence.
Head office
Gemin X Biotechnologies
3576 Avenue du Parc
Suite 4310
Montreal
Quebec
H2X 2H7
Quebec
Tel: (1) 514 281 8989
Fax: (1) 514 281 1065
www | email
3576 Avenue du Parc
Suite 4310
Montreal
Quebec
H2X 2H7
Quebec
Tel: (1) 514 281 8989
Fax: (1) 514 281 1065
www | email
Contact details
Dan Giampuzzi
CEO
CEO
Regional and subsidiary offices
To view this information, you must subscribe to PL Intelligence.
Related companies
Related categories
- Industry sector
- Biotechnology / Human therapeutics
- Drug discovery
- Pharmaceutical / Prescription
- Therapeutic target
- Oncology
© Copyright 1995-2009 Pharmalicensing, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us